Literature DB >> 17429708

Prognostic significance of receptor-binding cancer antigen expressed on SiSo cells (RCAS1) expression in relation to cadherin expression in patients with colorectal carcinoma.

Shunichi Tsujitani1, Hiroaki Saito, Takuya Honboh, Masayuki Ataka, Takashi Tanida, Masato Makino, Masahide Ikeguchi.   

Abstract

PURPOSE: This study was designed to assess the prognostic value of receptor-binding cancer antigen expressed on SiSo cells expression and its relationship with cadherin expression in patients with colorectal cancer.
METHODS: The expressions of receptor-binding cancer antigen expressed on SiSo cells and E-cadherin were analyzed with special reference to prognosis in 105 patients with colorectal cancer.
RESULTS: Receptor-binding cancer antigen expressed on SiSo cells immunoreactivity was detected in the membrane and cytoplasm of tumor cells and considered to be positive in 48 patients (45.7 percent). The expression of receptor-binding cancer antigen expressed on SiSo cells was significantly correlated with lymph node metastasis (P = 0.0004), venous invasion (P = 0.0062), Dukes stages (P < 0.0001), and serum levels of carcinoembryonic antigen (P = 0.014). Furthermore, receptor-binding cancer antigen expressed on SiSo cells expression was significantly correlated with a poor prognosis (P < 0.001), and multivariate analysis indicated that it was an independent prognostic indicator. The expression of receptor-binding cancer antigen expressed on SiSo cells was more frequently found in tumors with reduced or abnormal expression of E-cadherin. The survival time of patients with reduced/abnormal E-cadherin expression was significantly shorter than that of patients with normal E-cadherin expression among patients with receptor-binding cancer antigen expressed on SiSo cells expression (P = 0.0043) but did not differ for those without receptor-binding cancer antigen expressed on SiSo cells expression (P = 0.17). Furthermore, multivariate analysis revealed that reduced/abnormal expression of E-cadherin was an independent prognostic factor in patients with receptor-binding cancer antigen expressed on SiSo cells expression but not in those without receptor-binding cancer antigen expressed on SiSo cells expression.
CONCLUSIONS: Receptor-binding cancer antigen expressed on SiSo cells expression is significantly correlated with tumor progression and poor prognosis in patients with colorectal cancer. Both reduced E-cadherin and enhanced receptor-binding cancer antigen expressed on SiSo cells expression may be critical for the mechanism of metastasis and recurrence in human colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17429708     DOI: 10.1007/s10350-007-0223-8

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  4 in total

1.  The role of RCAS1 as a biomarker in diagnosing CRC and monitoring tumor recurrence and metastasis.

Authors:  Su-xia Han; Jing Wang; Li-juan Wang; Gui-hua Jin; Xia Ying; Chen-chen He; Xi-jing Guo; Jian-ying Zhang; Ying Zhang; Qing Zhu
Journal:  Tumour Biol       Date:  2014-03-21

2.  Clinical significance of tumor-associated antigen RCAS1 expression in human pancreatic ductal adenocarcinoma.

Authors:  Constantinos Giaginis; Demetrios Davides; Apostolos Zarros; Olga Noussia; Adamantia Zizi-Serbetzoglou; Gregorios Kouraklis; Stamatios Theocharis
Journal:  Dig Dis Sci       Date:  2008-06       Impact factor: 3.199

3.  Increased RCAS1 expression is associated with advanced histopathological stage and poor prognosis in patients with gastric adenocarcinoma.

Authors:  Constantinos Giaginis; Themistoclis Efkarpidis; Paraskevi Alexandrou; Efstratios Patsouris; Gregory Kouraklis; Stamatios Theocharis
Journal:  Dis Markers       Date:  2013-09-03       Impact factor: 3.434

4.  Identification of hub genes, key miRNAs and potential molecular mechanisms of colorectal cancer.

Authors:  Shasha Wu; Feixiang Wu; Zheng Jiang
Journal:  Oncol Rep       Date:  2017-08-29       Impact factor: 3.906

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.